Lalitha Krishna

The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma.

Background. A prospective study was conducted to evaluate the use of iodine‐131 sodium scintigraphy, thallium‐201 chloride scintigraphy, and quantitative serum thyroglobulin estimation in the detection of differentiated thyroid carcinoma after thyroidectomy and iodine‐131 sodium ablative therapy.

Marked bladder displacement by dilated rectosigmoid colon

A 22-year-old man admitted to the hospital after blunt trauma to the head, neck, flank, and abdomen developed sickle cell crisis, Escherichia coli sepis, tooth abscesses, and pain in his back and shoulders. Initial examination disclosed a massively dilated colon. A whole-body bone scan and a CT scan of the abdomen and pelvis were performed. Tc-99m HDP delayed bone images demonstrated abnormal uptake in multiple sites and a markedly displaced bladder, which emptied after voiding. The CT scan of the pelvis revealed a dilated stool-filled rectosigmoid displacing the bladder and loops of bowel

INDIUM-lll LABELLED ANTI EGFr-425 SCINTIGHAPHY IN THE DETECTION OF MALIGNANT GLIOMAS

BACKGROUND The monoclonal antibody anti-epidermal growth factor receptor (EGFr) antibody-425, against the epidermal growth factor receptor, has the potential to bind specifically to gliomas and not normal brain tissue. A prospective study was conducted (1986-1988) to evaluate the use of Indium-111 (111In)-labeled anti-EGFr-425 in the localization of gliomas before radioimmunotherapy with Iodine-125 (125I)-labeled anti-EGFr-425. METHODS Twenty-eight patients with intracranial neoplasms were injected intravenously with an average dose of 2.2 mCi 111In-labeled anti-EGFr-425. Planar and single-photon emission computed tomography scans were performed after 48 and 72 hours. Control studies also were performed in two cases with 111In-labeled Co 17-1A (an antibody to colorectal cancer) and in one case with unlabeled 111In chloride. RESULTS The immunoscintigraphic findings were generally in good agreement with computerized tomographic findings. The definitive diagnosis was established by biopsy findings: 23 gliomas (1 Grade I, 5 Grade II, 6 Grade III, and 11 Grade IV), 1 meningioma, and 4 metastatic lesions. The localization of gliomas with 111In-labeled anti-EGF-425 had a sensitivity of 0.96, a specificity of 0.60 and an accuracy of 0.90. CONCLUSION Immunoscintigraphy with 111-In labeled anti-EGFr-425 can be useful in the management of malignant gliomas, especially before radioimmunotherapy with 125I-labeled anti-EGFr-425.